The EFSD/Novo Nordisk Foundation Precision Diabetes Medicine Award Programme is funded by the European Foundation for the Study of Diabetes (EFSD) together with the Novo Nordisk Foundation to recognize and support research projects in precision diabetes medicine. Applicants must be members of the EASD. The award honors 1) the discovery of insulin in 1921, 2) its first use in humans in 1922, and 3) its Nobel Prize in 1923. The award is expected to accelerate important fields of translational research and to improve the speed of innovation implementation in diabetes care. Awards (to both clinicians and basic scientists) will be made in a total amount of Danish Krone (DKK) 1 awardee 2 million (~ €268,000) and 2 runners-up 500,000 DKK (~ €67,000) each to be paid to the awardee’s institution.
Grants may include up to 5% direct administrative expenses, which can cover non-scientific, administrative expenses in relation to the project, such as accounting, administration related to payment of salaries and purchasing, hiring, as well as auditing and financial reporting on the project. It cannot cover administrative expenses that are not directly related to the project. No Overheads will be granted.
Applications are due on May 15, 2023.
